Amgen gives Repatha, romosozumab updates

In its presentation Tuesday at the JPMorgan Healthcare Conference in San Francisco, Amgen Inc. (NASDAQ:AMGN) provided updates on the market position for lipid-lowering PCSK9 drug Repatha evolocumab and the clinical progress of postmenopausal osteoporosis candidate romosozumab ( AMG 785).

The company said about 80% of the hyperlipidemia market has access to Repatha, based on negotiated contracts with payers and PBMs. Amgen also presented data from IMS Health Inc., which showed prescription volumes for Repatha eclipsed those of competing product Praluent alirocumab at the end of October. Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) market Praluent. ...